Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential approval of AMX0035 for the treatment of ALS in countries other than Canada and the United States; statements regarding the timing of any regulatory re-examination process in Europe; the potential of AMX0035 as a treatment for ALS and the Company's plans to explore the use of AMX0035 for other neurodegenerative diseases, including progressive surpranuclear palsy and Wolfram syndrome; the potential market acceptance and market opportunity for RELYVRIO ® ; as well as access to and coverage for RELYVRIO; and expectations regarding our longer-term strategy.